Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Probi Interim / Quarterly Report 2023

Apr 26, 2023

3099_10-q_2023-04-26_69592a40-d6b6-440e-b564-5a70a9582a4b.pdf

Interim / Quarterly Report

Open in viewer

Opens in your device viewer

  • Net sales increased by 11% (2% adjusted for currency effects) to SEK 172 m (155).
  • The EBITDA margin amounted to 28% (25).
  • Positive one-off effects totaling SEK 18 m regarding postponed orders from Q4 2022.
  • Takeover of the distribution of our own brand Probi® in Sweden from April 1, 2023. New market organization established.
  • First commercial batch of spores produced.
  • Anita Johansen appointed CEO of Probi on March 30. Von Carlson took over as the new VP of Operations on March 27.

Jan-Mar Full-year
SEK m 2023 2022 RTM 2022
Net sales 171.8 154.7 635.4 618.3
Growth, % 11.1% -9.7% 2.8% -6.1%
Currency adjusted growth, % 2.1% -16.2% -9.0% -16.7%
Gross margin, % 42.5% 42.6% 41.3% 41.3%
EBITDA 47.3 38.3 145.2 136.3
EBITDA margin, % 27.5% 24.7% 22.9% 22.0%
Operating profit (EBIT) 23.6 18.5 55.7 50.6
EBIT margin, % 13.7% 12.0% 8.8% 8.2%
Net income 19.3 14.0 45.9 40.6
Earnings per share before and after dilution, SEK 1.69 1.23 4.03 3.57

See note 5 for definitions of ratios not defined according to IFRS

This information is information that Probi AB is obliged to make public pursuant to the EU Market Abuse Regulation. The Information was submitted for publication, through the agency of the CEO and CFO, on April 26, 2023 at 08:00 CET. This is a translation of the Swedish version of the interim report. When in doubt, the Swedish wording prevails.

With good help from exchange rates and one-off effects, we started the year with growth of 11% and an EBITDA margin of 28%. Growth amounted to 2% adjusted for currency effects, and postponed orders from Q4 had a one-off effect of SEK 18 m. Sales in the various regions have varied greatly during the quarter and do not provide a fully representative picture of the underlying position. Our assessment is that net sales for the first half of the year will be on par with or slightly below last year.

During Q1, the EMEA region was impacted by sell-out of stock by our former distributor in Sweden, affecting net sales, and decreasing in total in the region by 33% compared to the previous year. From April 1, we will distribute our own brand Probi® in Sweden. We have received a very good response so far and are satisfied with the contract negotiations that have been completed. Our sales are expected to pick up at the end of Q2, as a number of customers have purchased safety stock in connection with this transition. In general there is a certain cautiousness in the EMEA region's markets, but at the same time it is a stable region consisting of many longterm contract customers.

The APAC region delivered its strongest ever quarter with growth of 55%. At the same time, the fluctuations between the quarters are high and our assessment is that net sales will be at last year's level for the first six months. The growth potential in the region remains high with China as the driving force expanding its share of the region's sales even though Australia remains the largest market.

In the Americas region, we increased net sales by 18% during Q1, driven by currency effects and the postponed orders of SEK 18 m from Q4. Adjusted for this, growth was negative. The underlying development is mainly due to a slowdown in the market, where we saw a lower order frequency from our customers.

I was appointed CEO of Probi on March 30, which is a huge honor. At the same time, it means that we will start recruiting a new VP R&D. During Q1, we also strengthened management with a new VP of Operations, Von Carlson. He has a solid background in the production of probiotics from several companies, including DuPont Biosciences. After a couple of years of major investments in our manufacturing, we are entering a new phase where one of Von's most important missions will be to optimize our internal processes to increase efficiency. Against the background of our weak sales trend, we are also reviewing how we best meet our customers' needs and how we can become more efficient internally.

The results of our Gut-brain study are being finalized for publication. In dialogue with our customers, we have noted significant interest in this area and the publication of the study will give us the scientific support to be able to launch a new Gut-brain product, which we plan to do in the autumn.

We have not lived up to our goals and at the same time find ourselves in a challenging period. It is my top priority to get Probi back on the path to growth. Together with my management, I will invest a lot of time in improving our own processes and working methods. It will show us the way back to growth.

Anita Johansen CEO

Interim report January-March 2023

During Q1, net sales amounted to SEK 171.8 m (154.7), which corresponded to an increase of SEK 17.1 m or 11%. Adjusted for currency effects, net sales amounted to SEK 158.0 m, corresponding to an increase of 2%.

The increase of SEK 17.1 m is explained by higher sales in the Americas, which increased by SEK 19.7 m (18%) and APAC, which increased by SEK 7.5 m (55%). EMEA decreased by SEK 10.0 m (-33%).

The share of total net sales in the Americas during Q1 was 76%. EMEA accounted for 12% and APAC 12%.

Jan-Mar
SEK m 2023 2022 Change, %
Americas 130.7 111.0 17.7%
EMEA 20.0 30.0 -33.3%
APAC 21.2 13.7 54.7%
Net sales 171.8 154.7 11.1%

The operating profit for the quarter was SEK 23.6 m (18.5), which corresponded to an increase of SEK 5.1 m or 28%. Adjusted for currency effects, the operating profit was SEK 20.3 m. The improved operating profit was mainly due to higher sales.

Sales and marketing expenses amounted to SEK 26.3 m (23.4), with the increase explained by currency effects but also by an increase in costs in connection with the takeover of distribution in Sweden.

Research and development costs were at the previous year's level and amounted to SEK 9.7 m (9.2).

Administrative expenses decreased by SEK 1.5 m compared to last year and amounted to SEK 13.4 m (14.9). This reduction is mainly due to lower costs for personnel and business development.

Jan-Mar
SEK m 2023 2022 Change, %
Gross profit Americas 48.1 39.5 21.8%
Gross profit EMEA 11.0 17.5 -37.1%
Gross profit APAC 13.9 8.9 56.2%
Gross profit 73.0 65.9 10.8%
Sales and marketing expenses -26.3 -23.4 12.4%
Research and development expenses -9.7 -9.2 5.4%
Administration expenses -13.4 -14.9 -10.1%
Other operating income 0.0 0.1 0.0%
Operating profit (EBIT) 23.6 18.5 27.6%

The financial result for Q1 amounted to SEK 0.5 m (-0.9). Net financial items excluding exchange rate results amounted to SEK 0.8 m (-0.6) and consisted mainly of interest on leasing contracts. The exchange rate result amounted to SEK -0.3 m (-0.3) in Q1 and refers to the conversion of cash and cash equivalents into foreign currency.

The period's profit for the quarter amounted to SEK 19.3 m (14.0). Tax costs were SEK 4.8 m (3.6).

Earnings per share for the quarter amounted to SEK 1.69 (1.23).

Probi's operating segments are based on a geographical division and consist of the Americas (North and South America), EMEA (Europe, the Middle East and Africa) and APAC (Asia and the Pacific).

Net sales in the Americas increased by 18% and amounted to SEK 131 m. Adjusted for currency effects net sales amounted to SEK 118 m, corresponding to an increase of 6% during the quarter. There was a positive effect on net sales from postponed orders from Q4, corresponding to SEK 18 m.

The market was characterized by a certain slowdown and a lower order frequency among customers.

The gross margin in Q1 was 37% (36). The slightly improved gross margin is explained by higher sales volumes.

Jan-Mar
SEK m 2023 2022 Change, %
Net Sales 130.7 111.0 17.7%
Cost of goods sold -82.6 -71.5 15.5%
Gross profit 48.1 39.5 21.8%
Gross margin 36.8% 35.6% 1.2 ppt

Net sales in EMEA decreased by 33% in Q1 to SEK 20 m compared to SEK 30 m last year. Q1 was marked by our former distributor in Sweden selling off stock in connection as Probi took over the distribution of its own brand on the Swedish market. Sales are expected to pick up at the end of Q2, where a number of customers have purchased safety stock due to the transition.

The European market was characterized by a certain caution. At the same time, EMEA is a market with contract customers with long contracts, which provides stability.

The gross margin for Q1 was 55% (58). The lower margin is explained by reduced sales volumes.

Jan-Mar
SEK m 2023 2022 Change, %
Net Sales 20.0 30.0 -33.3%
Cost of goods sold -9.0 -12.5 -28.0%
Gross profit 11.0 17.5 -37.1%
Gross margin 55.3% 58.3% -3.0 ppt

Net sales in APAC were the highest ever and amounted to SEK 21 m, which corresponds to an increase of 55% compared to the previous year.

China is the driving force in the region and has greatly increased its share of sales. During Q1 we delivered our first order of BLIS to the Chinese market. Australia continues to be the region's largest market. The region is still characterized by major fluctuations and the assessment is that the net sales in the first half of the year will be on a par with last year.

The gross margin was in principle at the same level as last year and was 66% (65).

Jan-Mar
SEK m 2023 2022 Change, %
Net Sales 21.2 13.7 54.7%
Cost of goods sold -7.3 -4.8 52.1%
Gross profit 13.9 8.9 56.2%
Gross margin 65.8% 65.0% 0.8 ppt

Cash flow from operating activities before changes in working capital increased to SEK 47.0 m (38.8) in Q1 as a result of a higher operating profit.

Working capital increased during Q1 as a result of increased accounts receivable and a greater inventory, and cash flow from operating activities was SEK 12.8 m (37.9).

Cash flow from investment activities was SEK -14.3 m (-15.7) and mainly consisted of investments in tangible and intangible assets.

Cash flow from financing activities was SEK -3.8 m (-3.8) and mainly consisted of the amortization of leasing liabilities.

At the end of the period, cash flow amounted to SEK -5.8 m (20.2) and cash and cash equivalents amounted to SEK 318.0 m (271.2).

During Q1, investments in intangible fixed assets amounted to SEK 4.8 m (2.2), of which SEK 0.8 m (1.4) related to patents, SEK 1.8 m (0.8) related to capitalized development expenses and SEK 2.2 m (0.0) referred to IT systems. Investments in tangible fixed assets amounted to SEK 9.6 m (13.4), which mainly related to investments in the manufacturing unit at Redmond.

At the end of the period, Probi had 172 (176) employees, of which 52% (52) were women. The average number of employees during Q1 amounted to 163 (174).

During Q1, Probi reported SEK 0.0 m (0.6) in revenue from its largest shareholder, Symrise, and costs amounted to SEK 0.0 m (0.0). No other transactions with related parties occurred during the reporting period.

In February 2022, Russia launched an invasion of Ukraine. Probi has a limited exposure to Russia and Ukraine, and the company's assessment is that the effects at both supplier and customer levels are limited. The cost increases that have arisen in connection with increased inflation are mainly compensated by price increases to the customer. However, there may be a delayed effect until the price increases take full effect depending on the agreed terms.

In connection with Covid-19, it is mainly the risks surrounding changing consumer trends and the company's supply of goods that have become relevant. Other risks and uncertainty factors to which Probi's operations are exposed are described on pages 48–49 of the annual report for 2022.

During Q1, the parent company's operating income amounted to SEK 82.0 m (73.4). The profit for the period amounted to SEK 28.8 m (12.3) and this increase was due to a higher operating profit and an improved financial result. Investments in tangible and intangible assets amounted to SEK 2.9 m (5.1). For further details, please see the information for the Group.

Annual General Meeting 2023 May 4, 2023
Record date for dividend May 8, 2023
Payment date for dividend May 11, 2023
Interim report Q2 2023 July 18, 2023
Interim report Q3 2023 October 24, 2023
Year-end report 2023 January 26, 2024

Probi's interim report for Q1 2023 will be published on April 26, 2023, at 8:00 a.m. On the same day at 10:00 a.m., a telephone conference will be held with Anita Johansen, CEO and Henrik Lundkvist, CFO, who will present the report. The telephone conference can be accessed via the link

https://conference.financialhearings.com/teleconference/?id=200639. The presentation is available at www.probi.com and www.financialhearings.com.

Anita Johansen, CEO Telephone: +46 (0)46 286 89 48 E-mail: [email protected] Henrik Lundkvist, CFO Telephone: +46 (0)46 286 89 41 E-mail: [email protected]

The Board of Directors and CEO declare that this interim report provides a true and fair overview of the parent company's and Group's operations, financial position and results, and describes the significant risks and uncertainties facing the parent company and the Group.

Lund, April 26, 2023

Jean-Yves Parisot Chairman of the Board Jörn Andreas Board member

Irène Corthésy Malnoë Board member

Charlotte Hansson Board member

Malin Ruijsenaars Board member

Anita Johansen CEO

This interim report has not been subject to review by the company's auditors.

Jan-Mar
SEK 000 Notes 2023 2022
Net sales 2 171,819 154,718
Cost of goods sold 3 -98,815 -88,817
Gross profit 73,004 65,901
Sales and marketing expenses -26,306 -23,394
Research and development expenses -9,721 -9,203
Administration expenses -13,397 -14,896
Other operating income 83
Operating profit (EBIT) 23,580 18,491
Financial income 1,391 45
Financial expenses -543 -624
Exchange result financing activities 4 -348 -286
Financial result 500 -865
Earnings before income taxes 24,080 17,626
Income taxes -4,806 -3,607
Net income 19,274 14,019
Other comprehensive income
Components to be reclassified to net income
Exchange rate differences resulting from the translation of foreign operations -7,999 22,542
Cash flow hedge (currency hedges)
Income taxes payable on these components
Total components to be reclassified to net income -7,999 22,542
Components not to be reclassified to net income
Equity instruments at fair value through OCI 3,732 -4,328
Total components not to be reclassified to net income 3,732 -4,328
Sum of other comprehensive income -4,267 18,214
Total comprehensive income 15,007 32,233
Number of outstanding shares at end of the reporting period 11,394,125 11,394,125
Average number of shares 11,394,125 11,394,125
Earnings per share before and after dilution 1.69 1.23

The period's results as well as comprehensive income is attributable in its entirety to the parent company's shareholders. There is no dilution effect, as the company has no outstanding convertible loans or warrants.

Interim report January-March 2023

SEK 000 31 December 31 December
2023 2022
ASSETS
Capitalized development cost 24,264 24,782
Customer base 239,429 248,452
Technology and other intangible assets 104,692 109,251
Goodwill 351,088 353,887
Property, plant and equipment
Right-of-use assets
151,625
61,383
146,806
65,546
Interests in other entities 84,242 80,510
Deferred tax assets 339 357
Non-current assets 1,017,062 1,029,591
Inventories 127,994 116,245
Trade receivables 115,539 89,295
Other assets and receivables 11,647 11,051
Cash and cash equivalents 317,955 323,706
Current assets 573,135 540,297
Total assets 1,590,197 1,569,888
EQUITY AND LIABILITIES
Total equity 1,425,575 1,410,567
Deferred tax liabilities 11,822 13,833
Provisions 11,822 13,833
Non-current lease liabilities 49,511 53,601
Other non-current liabilities 5,436 5,480
Non-current liabilities 54,947 59,081
Trade payables 47,864 34,424
Current lease liabilities 16,670 16,667
Other current liabilities 33,319 35,316
Current liabilities 97,853 86,407
Total liabilities 164,622 159,321
Total equity and liabilities 1,590,197 1,569,888

SEK 000 Share
capital
Other
contri
butions
received
Cumulative
translation
differences
Hedging
reserve
Fair value
reserve
Accumulat
ed profit
Total
equity
Opening balance, 1 Jan 2022 58,221 600,205 29,414 -7721 585,422 1,265,541
Net income 14,019 14,019
Other comprehensive income 22,542 -4,328 18,214
Total Comprehensive Income 22,542 -4,328 14,019 32,233
Dividends
Total transactions with
shareholders
Closing balance, 31 Mar 2022 58,221 600,205 51,956 -12,049 599,441 1,297,774
SEK 000 Share
capital
Other
contri
butions
received
Cumulative
translation
differences
Hedging
reserve
Fair value
reserve
Accumulat
ed profit
Total
equity
Opening balance, 1 Jan 2023 58,221 600,205 169,322 -28,412 611,232 1,410,567
Net income 19,274 19,274
Other comprehensive income -7,999 3,732 -4,267
Total Comprehensive Income -7,999 3,732 19,274 15,007
Dividends
Total transactions with
shareholders
Closing balance, 31 Mar 2023 58,221 600,205 161,323 -24,680 630,506 1,425,575

Jan-Mar
SEK 000 2023 2022
Net income 19,274 14,019
Adjustments to reconcile net income to cash from
operating activities
Income taxes 4,806 3,607
Interest result -849 559
Amortization, depreciation and impairment of non-current assets 23,686 19,787
Other non-cash expenses and income 42 871
Cash flow before working capital changes 46,959 38,843
Change in trade receivables and other current assets -28,133 29,832
Change in inventories -12,694 -11,716
Change in trade payables and other current liabilities 10,980 -12,253
Income taxes paid -4,323 -6,793
Cash flow from operating activities 12,789 37,913
Payments for investing in intangible assets -4,753 -2,233
Payments for investing in property, plant and equipment -9,585 -13,430
Divestments of tangible assets
Cash flow from investing activities -14,338 -15,663
Interest paid -553 -612
Interest received 431 1
Repayments for lease obligations -3,681 -3,229
Dividends paid
Cash flow from financing activities -3,803 -3,840
Cash flow for the period -5,352 18,410
Effects of changes in exchange rates -399 1,769
Change in cash and cash equivalents -5,751 20,179
Cash and cash equivalents at opening balance 323,706 251,017
Cash and cash equivalents at closing balance 317,955 271,196

Jan-Mar
SEK 000 2023 2022
Operating revenue 82,011 73,448
Operating costs -18,850 -19,340
Gross profit 63,161 54,108
Operating profit (EBIT) 31,199 21,351
Result from financial income and expenses 4,266 -4,578
Income before tax 35,465 16,773
Net income 28,818 12,312
Jan-Mar
SEK 000 2023 2022
Net income 28,818 12,312
Sum of other comprehensive income
Total comprehensive income 28,818 12,312
SEK 000 31 December
2023
31 December
2022
ASSETS
Non-current assets 1,044,916 1,042,975
Current assets 320,849 299,369
Total assets 1,365,765 1,342,344
EQUITY AND LIABILITIES
Equity 1,329,349 1,300,531
Current liabilities 36,416 41,813
Total equity and liabilities 1,365,765 1,342,344

This interim report has been prepared in accordance with IAS 34 Interim Financial Reporting and the Swedish Annual Accounts Act. The condensed financial statements in the interim report are covered on pages 10-17. Disclosures in accordance with IAS 34 Interim Financial Reporting are provided both here and elsewhere in theinterim report. The ESMA guidelines on alternative performance measures apply.

The accounting principles applied when these consolidated accounts were prepared have been applied consistently for all periods presented, unless otherwise stated. Complete accounting principles can be found on pages 65–68 of the annual report for 2022.

The parent company's functional currency is Swedish kronor (SEK), which is also the reporting currency for both the parent company and the Group. All amounts stated are rounded to the nearest thousand kronor unless otherwise stated.

Amounts and figures in parentheses refer to comparative figures for the corresponding period of the previous year. Amounts are expressed in Swedish kronor (SEK), thousands (TSEK) or millions (SEK million) according to the unit stated.

The parent company applies the same accounting principles as the Group apart from IFRS 16 "Leasing" and with the exceptions and additions that appear in RFR 2 "Accounting for legal entities". The interim report complies with the Annual Accounts Act.

A breakdown by category of the Group's net sales from contracts with customers is presented below:

Jan-Mar 2023
Jan-Mar 2022
SEK 000 Americas EMEA APAC Total Americas EMEA APAC Total
Goods 128,670 19,035 21,167 168,872 109,446 29,277 13,671 152,394
Royalty 2,029 918 2,947 1,555 769 2,324
Net sales 130,699 19,953 21,167 171,819 111,001 30,046 13,671 154,718

The following table shows the exchange gains and losses from operating activities that are recognized under costof goods sold:

Jan-Mar
SEK 000 2023 2022
Exchange gains operating activities 987 1,732
Exchange losses operating activities -613 -1,066
Exchange result operating activities 374 666

The following table shows the exchange gains and losses from financing activities that are recognized in the financial results:

Jan-Mar
SEK 000 2023 2022
Exchange gains financing activities 837 815
Exchange losses financing activities -1,186 -1,101
Exchange result financing activities -349 -286

Probi presents certain financial key performance indicators (KPIs) in the interim report that are not defined according to IFRS. Probi believes that these indicators provide valuable supplementary information to investors and the company's management. Since not all companies calculate alternative KPIs in the same way, these are not always comparable to indicators used by other companies. However, these indicators should not be considered as a substitute for financial indicators required in accordance with IFRS. The following alternative KPIs are reported in the interim report:

The operating profit/loss (EBIT) is defined as the profit/loss before financial income, expenses and tax for the periodand is used as a measure of the company's profitability.

Jan-Mar
SEK 000 2023 2022
Net income 19,274 14,019
Income taxes 4,806 3,607
Financial result -500 865
Operating profit (EBIT) 23,580 18,491

EBITDA is defined as the operating profit (EBIT) before depreciation and impairment and is used as a measure of the company's profitability.

Jan-Mar
SEK 000 2023 2022
Operating profit (EBIT) 23,580 18,491
Depreciation and amortization 23,686 19,787
EBITDA 47,266 38,278

Interim report January-March 2023

Gross margin Defined as gross profit divided by
net sales
Used to measure product
profitability
EBITDA margin Defined as EBITDA divided by net
sales
Used to measure the company's
profitability before depreciation
and impairment of tangible and
intangible assets
Currency adjusted net sales
growth
Defined as net sales for the year
translated at the preceding year's
exchange rates divided by the
preceding year's net sales
Used to measure underlying net
sales growth
RTM Rolling twelve months. Refers to
full-year figure for the last four
quarters
Gives an indication of
development without having to
wait for the comparative period
next year
Operating margin Defined as the operating profit
divided by net sales
Used to measure the company's
profitability

Probi® is a global Group that focuses exclusively on research, manufacturing and delivery of probiotics in dietary supplements and food. The company has expertise in managing live bacteria from research through all stages of the manufacturing process and is dedicated to making the health-promoting benefits of probiotics available to people around the world. Since the company was founded in 1991 at Lund University in Sweden, Probi has expanded its operations to more than 40 markets and holds more than 400 patents worldwide. Probi had sales of SEK 618 m in 2022. Probi's shares are listed on Nasdaq Stockholm, Mid-cap, and there were around 3,700 shareholders on December 31, 2022.